All News

Suzetrigine could represent the first new nonopioid drug in a distinct class of pain medications in approximately 20 years.

Normalizing conversations around mental health in older adult populations can improve outcomes.

A conversation with Rakesh Jain, MD, MPH, clinical professor in the Department of Psychiatry at Texas Tech University School of Medicine.

In case you missed it, this week we had stories about medication adherence and breast cancer outcomes, new vaccines in the pipeline, independent pharmacies saying no to Medicare drug price, and more.

Acupuncture, a practice with thousands of years of history, has become increasingly accepted in mainstream medicine.

David Pope, PharmD, Chief Pharmacy Officer at XiFin, joined Drug Topics to discuss value-based care and how it has changed the way pharmacy operates.

Pharmacist management of chronic conditions can lead to improved patient outcomes.

Patients with chronic migraine can frequently overuse acute medications, leading to medication overuse headaches.

In posters presented at the American College of Clinical Pharmacy 2024 Annual Meeting, researchers explored the implementation of collaborative care programs within various health systems.

Cases of meningococcal disease currently exceed prepandemic levels.

The National Community Pharmacists Association surveyed over 4000 independent pharmacy owners and managers for their thoughts on the 10 drugs selected for Medicare price negotiations.

David Pope, PharmD, Chief Pharmacy Officer at XiFin, discussed pharmacy benefit managers and their impact on value-based care within pharmacies.

In an installment of Drug Topics’ 5 Questions With a Pharmacist, Stevie Veach of MercyOne Pharmacy in Dubuque, Iowa, talked about her pharmacy’s offerings and how they serve her community’s patients.

David Pope, PharmD, Chief Pharmacy Officer at XiFin, further discussed value-based care and his company’s ongoing collaboration with pharmacies across the country.

Posters presented at ACCP 2024 revealed gaps in pharmacy students’ understanding of off-label drug applications and identified strengths and weaknesses among pharmacy graduates.

The financial burden of in vitro fertilization (IVF) medications has become increasingly prohibitive, limiting the availability of fertility treatments for many.

Pharmacists can screen for social determinants of health and patient beliefs about medications as a way to improve adherence and subsequent outcomes in heart failure.

In a systematic review, researchers explored the role of clinical pharmacists within a multidisciplinary team treating patients with inflammatory bowel disease.

On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.

David Pope, PharmD, Chief Pharmacy Officer at XiFin, shared his thoughts on value-based care and how it is used within a pharmacy setting.

As health care systems and the current syndemic continue to evolve, pharmacies are poised to play a crucial role in improving public health.

Research presented at ACCP 2024 found that addiction medicine consult services could help increase medication for opioid use disorder initiation.

The FDA approved ceftobiprole medocaril sodium for injection (Zevtera) in April 2024.

Jon Minkin, enterprise account executive at NimbleRx, shared how his company can help independent pharmacies unlock revenue opportunities.

Erin Albert, vice president of pharmacy relations and chief privacy officer at Mark Cuban Cost Plus Drug Company, PBC, discussed drug pricing and what her company is doing to revolutionize transparency.

In case you missed it, this week we had stories about medication-related disaster preparedness, COVID-19 and cardiovascular risks, legal battles over inflated insulin prices, and more.

Check out important updates from the FDA for the week of October 7.

Marstacimab-hncq is the first non-factor and once-weekly treatment available for patients with hemophilia B and promises to reduce the burden of care.

A study published in Arteriosclerosis, Thrombosis, and Vascular Biology found the risk of major adverse cardiac events was higher in patients hospitalized with COVID-19.

The approval is supported by results from phase 3 multi-regional clinical trials conducted in patients with plaque psoriasis.